First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-

Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 8

Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) Director Bros. Advisors Lp Baker purchased 33,7

Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-b

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpo

What happened Kodiak Sciences Inc. (NASDAQ: KOD) cleared a pivotal hurdle for Zenkuda. The eye drug

Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal d

Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51

U.S. stocks fell Monday, led by a 150-point Nasdaq drop. Energy rose, communication services slid; K

U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints

UBS analyst Michael Yee maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price ta

Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's r

U.S. stocks fell Monday as the Dow dropped 200+ points; Nasdaq and S&P 500 also slid. Health car

HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Bu

Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with

Kodiak Sciences (KOD) is experiencing a significant surge in its stock price following the announcem

Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patien

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenku

Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) reached a new 52-week high during tra

Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharm

Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-ma

Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its

Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful

Kodiak Sciences to Host Webcast on Monday, September 28 PALO ALTO, Calif., Sept. 25, 2026 /PRNewswir

Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., S

Goldman Sachs analyst Andrea Newkirk reinstates Kodiak Sciences (NASDAQ:KOD) with a Neutral and a

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and va

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has been assigned a consensus recommendation of

HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a B

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's wort

Algert Global LLC increased its stake in shares of Kodiak Sciences Inc. (NASDAQ: KOD) by 26.1% durin

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a B

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical dat

Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst

Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients wit

JP Morgan analyst Anupam Rama maintains Kodiak Sciences (NASDAQ:KOD) with a Overweight and raises

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Top analysts upgraded Starz Entertainment, Primoris Services, Pitney Bowes, Kodiak Sciences, and Sta

Chardan Capital analyst Daniil Gataulin upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Buy

Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.94) per share which missed the analyst

The small-cap Russell 2000 punched through to an intraday record high on Friday, capping a furious 1

U.S. stocks rise, Dow Jones up 400+ points. PVH Corp beats expectations, shares jump 9.9%. Other big

U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.

The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, w